Plain-English translation of NCT07109986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study of a new treatment called designed for people with lupus that hasn't improved with standard medicines. The study will test whether this medication is safe and how well it works in adults with active lupus, including those whose kidneys are affected (a serious form called lupus nephritis). Researchers will gradually increase the dose to find the right amount that is both safe and effective.
Many people with lupus don't respond well enough to existing treatments, and their disease continues to cause serious damage. This medication represents a new approach to treating lupus that hasn't been tested in humans before, and researchers hope it could help people whose lupus is hard to control.
You likely qualify if…
You likely don't qualify if…
You would receive a single infusion of the medication through an IV on day 1 of the study. The research team will monitor you closely for 28 days after treatment to watch for side effects, and then follow up with you at multiple visits over 24 months (around 1, 2, 3, 6, 9, 12, 18, and 24 months) to see how your lupus responds. During these visits, you'll have blood tests and assessments of your lupus activity.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China